C18-Ceramide (d18:1/18:0)
CAS No. : 2304-81-6
(Synonyms: C18-Ceramide)
| Size | Price | Stock |
|---|---|---|
| 5mg | $80 | In-stock |
| 10mg | $135 | In-stock |
| 25mg | $270 | In-stock |
| 50mg | $432 | In-stock |
| 100mg | $692 | In-stock |
| 200 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-100355 |
| M.Wt: | 565.95 |
| Formula: | C36H71NO3 |
| Purity: | >98 % |
| Solubility: | Ethanol : 5 mg/mL (ultrasonic);DMSO : < 1 mg/mL (ultrasonic;warming;heat to 60°C);DMF : 1 mg/mL (ultrasonic) |
C18-Ceramide (d18:1/18:0) is a bioactive molecule with multiple functions in cells, not a traditional agonist or inhibitor targeting a single site. It can act on multiple cellular targets, such as proteins related to endoplasmic reticulum stress (e.g., ATF-4, XBP-1, CHOP), proteins in the PI3K/AKT signaling pathway, and SNARE complex proteins. It exerts activities like inducing cell death, promoting autophagy, and regulating exocytosis through mechanisms such as activating endoplasmic reticulum stress, inhibiting the PI3K/AKT signaling pathway, and affecting lipid raft - related functions. It can be used in research on the mechanism of neuronal injury in the field of neuroscience and in the treatment research of cancers such as glioma in the field of oncology[1][2].
In Vitro: In the PC12 cell capacitance measurement experiment, C18-Ceramide (d18:1/18:0) (2 μM; transient) can significantly increase the cell membrane capacitance, indicating that it can promote exocytosis[1].
In the PC12 cell total internal reflection fluorescence microscopy (TIRFM) experiment, C18-Ceramide (d18:1/18:0) (2 μM) can rapidly reduce the number of NPY-EGFP-labeled subcellular membrane vesicles, which undergo endocytosis by fusing with the cell membrane[1].
In U251 and A172 glioma cells, C18-Ceramide (d18:1/18:0) (20 μM; 48 h) inhibits glioma cell viability and induces cell death[2].
C18-Ceramide (d18:1/18:0) (20 μM; 48 h) activates endoplasmic reticulum stress and increases the mRNA and protein levels of ATF-4, XBP-1 (s) and CHOP[2].
C18-Ceramide (d18:1/18:0) induced lethal autophagy, increased the punctate distribution and density of GFP-LC3, promoted the conversion of LC3B-I to LC3B-II and decreased the level of p62[2].
C18-Ceramide (d18:1/18:0) inhibited the PI3K/AKT pathway and decreased the expression levels of PI3K and p-AKT (S473)[2].
C18-Ceramide (d18:1/18:0) (20μM; co-treatment with VM-26 for 48h) increased the chemosensitivity of U251 and A172 cells to VM-26 (HY-13761), synergistically inhibited cell growth, and induced more apoptosis[2].
In Vivo: In the rat Kainate injury model, C18-Ceramide (d18:1/18:0) has an increasing content in the brain after injury. C18-Ceramide (d18:1/18:0) might facilitate the exocytosis of glutamate from damaged neurons, thus propagating neuronal injury[1].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- C18-Ceramide (d18:1/18:0)
- Cat. No.:
- HY-100355
- Quantity:
Your information is safe with us.